Ari Rosenberg to Humans
This is a "connection" page, showing publications Ari Rosenberg has written about Humans.
Connection Strength
0.411
-
Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Controlled Trial. JAMA Oncol. 2024 Jul 01; 10(7):923-931.
Score: 0.031
-
Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy. Am Soc Clin Oncol Educ Book. 2024 Jun; 44(3):e433330.
Score: 0.030
-
Evolutionary dynamics of tipifarnib in HRAS mutated head and neck squamous cell carcinoma. Oral Oncol. 2024 Feb; 149:106688.
Score: 0.030
-
A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer. Ann Oncol. 2023 08; 34(8):714-722.
Score: 0.028
-
Recommendations for Care of Survivors of Head and Neck Cancer. JAMA. 2022 10 25; 328(16):1637-1638.
Score: 0.027
-
Phase I study of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma. Br J Cancer. 2022 11; 127(8):1497-1506.
Score: 0.027
-
Induction Chemotherapy in Low-Risk HPV+ Oropharyngeal Cancer. Curr Treat Options Oncol. 2022 01; 23(1):54-67.
Score: 0.026
-
Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment. BMC Cancer. 2022 Jan 03; 22(1):17.
Score: 0.026
-
Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience. Oral Oncol. 2021 11; 122:105566.
Score: 0.025
-
Multimodality Therapy for Locoregional Nasopharyngeal Carcinoma-A Decision Tool for Treatment Optimization. JAMA Netw Open. 2020 12 01; 3(12):e2030672.
Score: 0.024
-
Optimizing Treatment De-Escalation in Head and Neck Cancer: Current and Future Perspectives. Oncologist. 2021 01; 26(1):40-48.
Score: 0.024
-
Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up. Oncologist. 2019 08; 24(8):1039-e642.
Score: 0.022
-
Epithelioid Hemangioendothelioma: Update on Diagnosis and Treatment. Curr Treat Options Oncol. 2018 03 15; 19(4):19.
Score: 0.020
-
Utility of the revised cardiac risk index for predicting postsurgical morbidity in Hb SC and Hb Sß+-thalassemia sickle cell disease. Am J Hematol. 2016 06; 91(6):E316-7.
Score: 0.017
-
PRMT5 inhibition has a potent anti-tumor activity against adenoid cystic carcinoma of salivary glands. J Exp Clin Cancer Res. 2025 Jan 11; 44(1):11.
Score: 0.008
-
A comprehensive AI-driven analysis of large-scale omic datasets reveals novel dual-purpose targets for the treatment of cancer and aging. Aging Cell. 2023 12; 22(12):e14017.
Score: 0.007
-
New insights into RAS in head and neck cancer. Biochim Biophys Acta Rev Cancer. 2023 11; 1878(6):188963.
Score: 0.007
-
Mutated HRAS Activates YAP1-AXL Signaling to Drive Metastasis of Head and Neck Cancer. Cancer Res. 2023 04 04; 83(7):1031-1047.
Score: 0.007
-
AL101, a gamma-secretase inhibitor, has potent antitumor activity against adenoid cystic carcinoma with activated NOTCH signaling. Cell Death Dis. 2022 08 05; 13(8):678.
Score: 0.007
-
Application of liquid biopsy as multi-functional biomarkers in head and neck cancer. Br J Cancer. 2022 02; 126(3):361-370.
Score: 0.006
-
A robust and interpretable gene signature for predicting the lymph node status of primary T1/T2 oral cavity squamous cell carcinoma. Int J Cancer. 2022 02 01; 150(3):450-460.
Score: 0.006
-
Novel Strategies to Effectively De-escalate Curative-Intent Therapy for Patients With HPV-Associated Oropharyngeal Cancer: Current and Future Directions. Am Soc Clin Oncol Educ Book. 2020 Mar; 40:1-13.
Score: 0.006